Biotech Gwth Regulatory News (BIOG)

London, UK, 24 January 2020

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital. They remain optimistic about the prospects for the sector in 2020 due to high levels of innovation and a relaxed regulatory environment, while a continuation in merger and acquisition (M&A) activity would also likely provide further support for biotech shares. The managers are very encouraged by the trust's much-improved investment performance in recent months, noting they are being rewarded by the market for their in-depth fundamental research and portfolio positioning in favour of emerging rather than large-cap biotech stocks. BIOG's NAV has now outperformed the NASDAQ Biotechnology index benchmark over the last one, three, five and 10 years.

BIOG is currently trading at a 9.1% discount to cum-income NAV, which compares to a 5.4% to 7.9% range of discounts over the last one, three, five and 10 years. There is scope for a higher valuation given the meaningful recent improvement in the trust's performance. The board actively repurchases shares, aiming for a maximum 6% discount in normal market conditions.

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group- 

Twitter www.twitter.com/Edison_Inv_Res 

YouTube www.youtube.com/edisonitv